Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis;Vrednosti faktora nekroze tumora alfa i interleukina 4 u likvoru i plazmi bolesnika sa različitim formama multiple skleroze

Vojnosanitetski Pregled

Volumn 69, Issue 2, 2012, Pages 151-156

  Obradović, Dragana ^a   Kataranovski, Milena ^a   Dinčić, Evica ^a   Obradović, Slobodan ^a   Čolić, Miodrag ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Cerebrospinal fluid; Disease progression; Interleukin 4; Multiple sclerosis; Plasma; Treatment outcome; Tumor necrosis factor alpha

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REMISSION;

ADULT; FEMALE; HUMANS; INTERLEUKIN-4; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856661087     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1202151O     Document Type: Article

References (45)

1. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45(6 Suppl 6): S11-5.
2. Galboiz Y, Miller A. Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol 2002; 15(3): 233-7.
3. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361(9): 888-98.
4. Yong VW, Marks S. The interplay between the immune and central nervous systems in neuronal injury. Neurology 2010; 74 Suppl 1: S9-S16.
5. Miller A, Galboiz Y. Multiple sclerosis: from basic immunopathology to immune intervention. Clin Neurol Neurosurg 2002; 104(3): 172-6.
6. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5): 1175-89.
7. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler 2002; 8(5): 396-404.
8. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7(3): 115-21.
9. Lonergan R, Kinsella K, Duggan M, Jordan S, Hutchinson M, Tubridy N. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler 2009; 15(12): 1528-31.
10. Vladić A, Horvat G, Vukadin S, Sucić Z, Simaga S. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 2002; 20(2): 86-9.
11. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991; 104(2): 230-4.
12. Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32(1): 67-74.
13. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23(4): 339-46.
14. Hartung HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995; 45(6 Suppl 6): S22-32.
15. Armstrong MA, McDonnell GV, Graham CA, Kirk CW, Droogan AG, Hawkins SA. Relationship between tumour necrosis factor- alpha (TNFalpha) production and a specific multiple sclerosis (MS) associated TNF gene haplotype. Mult Scler 1999; 5(3): 165-70.
16. Hartung HP. Pathogenesis of multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis: clinical research and therapy. London: Martin Dunitz; 1997. p. 45-9.
17. Link J. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol Scand Suppl 1994; 158: 1-58.
18. Söderström M, Hillert J, Link J, Navikas V, Fredrikson S, Link H. Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Mult Scler 1995; 1(3): 173-80.
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3): 227-31.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
21. Tourtellotte WW, Ma BI. Multiple sclerosis: the blood-brainbarrier and the measurement of de novo central nervous system IgG synthesis. Neurology 1978; 28(9 Pt 2): 76-83.
22. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995; 45(6 Suppl 6): S16-21.
23. Głabiński A, Mirecka M, Pokoca L. Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. Acta Neurol Scand 1995; 91(4): 276-9.
24. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37(1): 82-8.
25. Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004; 10(2): 165-9.
26. Baraczka K, Nékám K, Pozsonyi T, Szüts I, Ormos G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur J Neurol 2004; 11(1): 37-42.
27. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325(7): 467-72.
28. Eikelenboom MJ, Killestein J, Uitdehaag BM, Polman CH. Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis. Mult Scler 2005; 11(5): 520-3.
29. Durán I, Martínez-Cáceres EM, Brieva L, Tintoré M, Montalban X. Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. Mult Scler 2001; 7(3): 151-6.
30. Jovičić A, Djordjević D, Marić D, Raičević R. New findings on reactive oxidative materials and their role in biological systems. Vojnosanit Pregl 1995; 52(6): 579-84. (Serbian)
31. Jovičić A, Jovanović M, Djordjević D, Magdić B, Dinčić E, Maličević Z. Oxidative and antioxidative activity in the patients with disseminated demyelinating disease of central nervous system. Vojnosanit Pregl 1997; 54(3): 193-202. (English, Serbian)
32. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995; 242(2): 53-8.
33. van Winsen LM, Polman CH, Dijkstra CD, Tilders FJ, Uitdehaag BM. Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis. Mult Scler 2010; 16(4): 500-2.
34. Lalive PH, Burkhard PR, Chofflon M. TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapse. Behav Neurosci 2002; 116(6): 1093-7.
35. Kleine TO, Zwerenz P, Graser C, Zöfel P. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull 2003; 61(3): 327-46.
36. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009; 45(2): 55-7.
37. Ossege LM, Sindern E, Patzold T, Malin JP. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis. Int Immunopharmacol 2001; 1(6): 1085-100.
38. Clerici M, Saresella M, Trabattoni D, Speciale L, Fossati S, Ruzzante S, et al. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J Neuroimmunol 2001; 121(1-2): 88-101.
39. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146(1-2): 209-15.
40. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 2004; 127(Pt 6): 1313-31.
41. Te Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG. Interleukin- 4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood 1990; 76(7): 1392-7.
42. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 2010; 23(3): 205-11.
43. Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10(5): 791-809.
44. Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16(2): 208-17.
45. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010; 74 Suppl 1: S31-40.